GSK’s new asthma drug Relvar Ellipta has shown itself to be superior to existing treatments in a major real world trial, the Salford Lung Study (SLS). Developed with US respiratory specialist ...

The results further undermine Relvar Ellipta, which is already struggling to establish itself in the COPD market. The drug is positioned as a follow-up product to GSK’s blockbuster Advair ...

Singapore’s Health Sciences Authority (HSA) has expanded the label of GlaxoSmithKline (GSK)’s Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) to ...

GSK plc GSK reported fourth-quarter 2024 core earnings of 59 cents per American depositary share (ADS), which beat the Zacks Consensus Estimate of 53 cents. Core earnings declined 20% year over year ...

Astellas Pharma’s prostate cancer drug, Xtandi, is also on the list — alongside AstraZeneca’s cancer treatment Calquence, GSK’s chronic obstructive pulmonary disorder (COPD) drug Breo Ellipta, and ...

GSK Plc's (NYSE:GSK) Asthma and Chronic obstructive pulmonary disease treatment Trelegy Ellipta and Breo Ellipta. Teva Pharmaceutical Industries Ltd.'s (NYSE:TEVA) Huntington's disease and Tardive ...

GSK plc GSK reported fourth-quarter 2024 core ... the upside was primarily driven by solid sales growth of asthma inhaler Trelegy Ellipta across all regions. This was partially offset by the ...